Concepedia

Jaya Natarajan

JN

Statistics

Publications

30

Citations

1.6K

H-Index

21

Active since

1994

Affiliations

Johnson & Johnson (United States)(Current)

Janssen (United States)

Swansea University

Janssen (Belgium)

Jaya Natarajan is an author at Johnson & Johnson (United States) specializing in pharmacology, clinical pharmacology, and pharmacokinetics.

Publications per year

1994–2023

30

Publications

30

Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

Sue Sha, David Polidori, Tim Heise et al. · Diabetes Obesity and Metabolism · 2014 · 244 citations

Medicine, Pharmacology, Pharmacotherapy +17

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

Shuchean Chien, Mark Rogge, L. G. Gisclon et al. · Antimicrobial Agents and Chemotherapy · 1997 · 217 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Levofloxacin Population Pharmacokinetics and Creation of a Demographic Model for Prediction of Individual Drug Clearance in Patients with Serious Community-Acquired Infection

Sandra L. Preston, George L. Drusano, Adam L. Berman et al. · Antimicrobial Agents and Chemotherapy · 1998 · 117 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study

Sue Sha, David Polidori, Kristin Farrell et al. · Diabetes Obesity and Metabolism · 2014 · 92 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Pharmacokinetics of a contraceptive patch (Evra<sup>™</sup>/Ortho Evra<sup>™</sup>) containing norelgestromin and ethinyloestradiol at four application sites

Larry S. Abrams, Donna Skee, Jaya Natarajan et al. · British Journal of Clinical Pharmacology · 2002 · 92 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

1–5 of 30